Hepatosplenic T-Cell Lymphoma
Associated Genetic Biomarkers
NCI Definition: An extranodal, mature T-cell non-Hodgkin lymphoma that originates from cytotoxic T-cells, usually of gamma/delta T-cell type. It is characterized by the presence of medium-size neoplastic lymphocytes infiltrating the hepatic sinusoids. A similar infiltrating pattern is also present in the spleen and bone marrow that are usually involved at the time of the diagnosis. 
There are 10 clinical trials for hepatosplenic T-cell lymphoma, of which 8 are open and 2 are completed or closed. Of the trials that contain hepatosplenic T-cell lymphoma as an inclusion criterion, 1 is early phase 1 (1 open), 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), 4 are phase 2 (3 open), and 1 is no phase specified (1 open).
ALK and FLT3 are the most frequent gene inclusion criteria for hepatosplenic T-cell lymphoma clinical trials .
Cyclophosphamide, allogeneic hematopoietic stem cell transplantation, and brentuximab vedotin are the most common interventions in hepatosplenic T-cell lymphoma clinical trials.
Significant Genes in Hepatosplenic T-Cell Lymphoma
ALK is an inclusion eligibility criterion in 2 clinical trials for hepatosplenic T-cell lymphoma, of which 2 are open and 0 are closed. Of the trials that contain ALK status and hepatosplenic T-cell lymphoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) .
FLT3 is an inclusion eligibility criterion in 1 clinical trial for hepatosplenic T-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains FLT3 status and hepatosplenic T-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.